7,12-Dimethylbenz(a)anthracene
Appearance
Names | |
---|---|
IUPAC name
7,12-Dimethylbenzo[a]phenanthrene
| |
Other names
7,12-Dimethylbenzanthracene; 7,12-Dimethyltetraphene; 1,4-Dimethyl-2,3-benzophenanthrene
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.000.326 |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H16 | |
Molar mass | 256.348 g·mol−1 |
Melting point | 122 to 123 °C (252 to 253 °F; 395 to 396 K) |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
T (Toxic) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen.[2] DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis.[3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.
References
- ^ 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
- ^ Miyata M, Furukawa M, Takahashi K, Gonzalez FJ, Yamazoe Y (2001). "Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ". Jpn J Pharmacol. 86: 302–309. doi:10.1254/jjp.86.302.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Sung YM, He G, Fischer, SM (2005). "Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development". Cancer Res. 65: 9304–9311. doi:10.1158/0008-5472.can-05-1015.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)